news
EMA’s human medicines committee (CHMP) September meeting highlights
In its most recent meeting, the CHMP recommended nine new medicines and concluded its review of Vaxzevria’s thrombosis risk.
List view / Grid view
rivaroxaban
article
Summarising 2019: a year of firsts for the EMA
The EMA was a proactive force in 2019, granting marketing authorisation for a range of drugs. This article highlights some of the most important advancements made by the agency last year.
news
SMC accepts restricted use of rivaroxaban for CAD
The SMC has approved a drug, called rivaroxaban, that targets Factor Xa to treat those with coronary artery disease (CAD)...
news
Rivaroxaban reduced blood clots and related death in cancer patients
Through a clinical trial, Cleveland researchers have identified how rivaroxaban reduces blood clots in cancer patients and also decreases related deaths...
news
New anti-clotting drugs linked to lower risk of serious bleeding
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
news
FDA approves new dosing for Xarelto to reduce the risk of VTE
The FDA has approved the 10 mg once-daily dose of Xarelto, for reducing the continued risk of recurrent venous thromboembolism...
news
Anticoagulant drugs appear to reduce the risk of stroke in patients with AF
Blood-thinning drugs not only reduce the risk of stroke in patients with AF but are also associated with a significant reduction in the risk of dementia...
news
FDA Advisory Committee recommends against approval of the use of oral anticoagulant XARELTO® to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome
16 January 2014 | By Johnson & Johnson
Janssen is seeking approval of rivaroxaban at a proposed dose of 2.5 mg twice daily (BID) for a 90 day treatment duration...
news
Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed
24 August 2012 | By Boehringer Ingelheim
Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation...
news
Bayer’s Xarelto® approved in the EU for the prevention of stroke in patients
20 December 2011 | By Bayer HealthCare
The only new oral anticoagulant approved in three indications across all 27 EU member states...
